MeSH Review:
Orphan Drug Production
- A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis. Soohoo, N., Schneider, J.A., Kaplan, R.M. Medical decision making : an international journal of the Society for Medical Decision Making. (1997)
- Analysis of D-penicillamine by gas chromatography utilizing nitrogen--phosphorus detection. Rushing, L.G., Hansen, E.B., Thompson, H.C. J. Chromatogr. (1985)
- 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Molgó, J., Guglielmi, J.M. Pflugers Arch. (1996)
- Development of an orphan drug by a start-up company. MetroGel for rosacea. Borgman, R.J. International journal of technology assessment in health care. (1992)
- Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Cohen, M.H., Moses, M.L., Pazdur, R. Oncologist (2002)
- meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Aposhian, H.V., Aposhian, M.M. Annu. Rev. Pharmacol. Toxicol. (1990)
- Dornase-alfa and orphan drugs. Collier, J. Lancet (1995)
- Lithium: an orphan drug. Rosenthal, N.E. Arch. Gen. Psychiatry (2001)
- Orphan drugs: creating a policy. Asbury, C.H., Stolley, P.D. Ann. Intern. Med. (1981)
- PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hershfield, M.S. Hum. Mutat. (1995)
- Topical metronidazole: a new therapy for rosacea. Schmadel, L.K., McEvoy, G.K. Clinical pharmacy. (1990)
- Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act. Liu, D.T. Trends Biotechnol. (1992)
- Allergic reactions to Triatoma bites. Moffitt, J.E., Venarske, D., Goddard, J., Yates, A.B., deShazo, R.D. Ann. Allergy Asthma Immunol. (2003)
- Methadone: an orphan drug? Ripamonti, C., Bianchi, M., Bruera, E. Journal of palliative medicine. (2004)
- Imatinib. Novartis. Radford, I.R. Current opinion in investigational drugs (London, England : 2000) (2002)
- Orphan drug development is progressing too slowly. Joppi, R., Bertele, V., Garattini, S. British journal of clinical pharmacology. (2006)
- Orphan drugs and the NHS: should we value rarity? McCabe, C., Claxton, K., Tsuchiya, A. BMJ (2005)
- CMS move threatens to put orphan drugs out in cold. Carroll, J. Managed care (Langhorne, Pa.) (2003)
- Protease inhibitors in the treatment of hereditary angioedema. Ritchie, B.C. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. (2003)